200 related articles for article (PubMed ID: 21162698)
1. Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells.
Taur JS; DesJardins CS; Schuck EL; Wong YN
Xenobiotica; 2011 Apr; 41(4):320-6. PubMed ID: 21162698
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
3. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
[TBL] [Abstract][Full Text] [Related]
4. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
5. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
6. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Zhang ZY; King BM; Pelletier RD; Wong YN
Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
[TBL] [Abstract][Full Text] [Related]
7. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
8. A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice.
Mason BL; Pariante CM; Thomas SA
Endocrinology; 2008 Oct; 149(10):5244-53. PubMed ID: 18556350
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
[TBL] [Abstract][Full Text] [Related]
10. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
11. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
12. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
[TBL] [Abstract][Full Text] [Related]
13. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells.
Zhang S; Morris ME
Pharm Res; 2003 Aug; 20(8):1184-91. PubMed ID: 12948016
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Lagas JS; van Waterschoot RA; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Cancer Ther; 2010 Feb; 9(2):319-26. PubMed ID: 20103600
[TBL] [Abstract][Full Text] [Related]
15. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Collett A; Tanianis-Hughes J; Hallifax D; Warhurst G
Pharm Res; 2004 May; 21(5):819-26. PubMed ID: 15180340
[TBL] [Abstract][Full Text] [Related]
16. [
Mairinger S; Leterrier S; Filip T; Löbsch M; Pahnke J; Hernández-Lozano I; Stanek J; Tournier N; Zeitlinger M; Hacker M; Langer O; Wanek T
J Cereb Blood Flow Metab; 2024 Jan; 44(1):142-152. PubMed ID: 37728771
[TBL] [Abstract][Full Text] [Related]
17. The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells.
Yue GG; Cheng SW; Yu H; Xu ZS; Lee JK; Hon PM; Lee MY; Kennelly EJ; Deng G; Yeung SK; Cassileth BR; Fung KP; Leung PC; Lau CB
J Med Food; 2012 Mar; 15(3):242-52. PubMed ID: 22181075
[TBL] [Abstract][Full Text] [Related]
18. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Cortes J; Lorca R
Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals.
Wang JS; Taylor R; Ruan Y; Donovan JL; Markowitz JS; Lindsay De Vane C
Neuropsychopharmacology; 2004 Mar; 29(3):551-7. PubMed ID: 14702023
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
